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Background: Although significant progress has been made in clinical trials of women-controlled methods of HIV
prevention such as microbicides and Pre-exposure Prophylaxis (PrEP), low adherence to experimental study
products remains a major obstacle to being able to establish their efficacy in preventing HIV infection. One factor
that influences adherence is the ability of trial participants to attend regular clinic visits at which trial products are
dispensed, adherence counseling is administered, and participant safety is monitored. We conducted a qualitative
study of the social contextual factors that influenced adherence in the VOICE (MTN-003) trial in Johannesburg,
South Africa, focusing on study participation in general, and study visits in particular.
Methods: The research used qualitative methodologies, including in-depth interviews (IDI), serial ethnographic
interviews (EI), and focus group discussions (FGD) among a random sub-sample of 102 female trial participants,
18 to 40 years of age. A socio-ecological framework that explored those factors that shaped trial participation and
adherence to study products, guided the analysis. Key codes were developed to standardize subsequent coding
and a node search was used to identify texts relating to obstacles to visit adherence. Our analysis includes coded
transcripts from seven FGD (N = 40), 41 IDI, and 64 serial EI (N = 21 women).
Results: Women’s kinship, social, and economic roles shaped their ability to participate in the clinical trial. Although
participants expressed strong commitments to attend study visits, clinic visit schedules and lengthy waiting times
interfered with their multiple obligations as care givers, wage earners, housekeepers, and students.
Conclusions: The research findings highlight the importance of the social context in shaping participation in HIV
prevention trials, beyond focusing solely on individual characteristics. This points to the need to focus interventions
to improve visit attendance by promoting a culture of active and engaged participation.
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Adherence has emerged as a particularly critical issue
for clinical trials of user-dependent technologies such as
Pre Exposure Prophylaxis (PrEP), delivered as tablets or
vaginal gels [1-3]. Understanding what shapes adherence
to investigational products has therefore generated much
attention in the recent literature [4]. There is broad
agreement that adherence is an individual behavior but* Correspondence: Jstadler@wrhi.ac.za
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unless otherwise stated.is shaped by a complex mix of social, cultural, and
economic factors [5]. The demographic and behavioral
characteristics of trial participants, the acceptability of
investigational products, and the community context,
may all have a bearing on adherence decisions and cap-
abilities. Regular supply of investigational product how-
ever is a fundamental precondition for trial participants
to be adherent, and this requires regular attendance at
clinic visits. In a systematic review of the barriers and
facilitators to adherence in 24 HIV prevention trials
conducted in African countries, low adherence in three
studies was due to the lack of study product whenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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absenteeism from the study area as a major barrier to
adherence, implying lack of access to product due to
missed visits [6]. Moreover, at clinic visits, trial staff do
not only dispense product and administer adherence
counseling, but also monitor participant safety and assess
trial endpoints.
Studies of visit retention in HIV prevention trials have
focused on socio-demographic factors such as age, mo-
bility, and risk behaviors [7,8]. Of particular concern in
PrEP and microbicide trials is the focus on younger
women, who are most at risk of HIV acquisition [9,10].
Their vulnerability to infection is attributed to the ‘com-
plex interplay of biological, social, cultural and political
factors’ [11], that underlie powerlessness to negotiate
‘safer sex’, and insist on condom use [12]. These same
social characteristics contribute towards instability and
poor prospects for being retained in trials than older,
more stable individuals. Younger women tend to have
high rates of discontinuation or being lost to follow up
[7]. Highly mobile populations are also difficult to retain
due to the frequency and duration of study visits [13].
Visit retention may be supported by various strategies:
participant-tracking; home and workplace visits; short
messaging service (SMS) reminders; global positioning
system (GPS) locators; improving the quality of clinical
services; rewards and incentives for visit completion
[13]. These strategies are primarily individual motiv-
ational strategies. Yet, trial participation can be influ-
enced by the social and cultural contexts and everyday
life processes. Relationships within the domestic domain
with family members, partners, and within communities
may constrain intentions and decisions to participate in
a trial. While reasons for missing clinic visits may often
be idiosyncratic and related to individual characteristics,
there is a need to better understand the social context in
which trials take place and its influence on participants’
abilities to keep to a clinic visit schedule.
The recently completed VOICE trial (MTN-003) was a
Phase 2 B safety and effectiveness study of daily Tenofo-
vir 1% gel, Tenofovir Disoproxil Fumarate tablet and
Emtricitabine/Tenofovir Disoproxil Fumarate tablet for
the prevention of HIV infection in women. The trial
enrolled a total of 5029 HIV negative women in three
countries (Uganda, Zimbabwe and South Africa) [14].
As a planned ancillary qualitative study to VOICE,
VOICE-C was conducted at one site, Johannesburg,
South Africa, concurrently to the VOICE trial. This sub-
study aimed to explore contextual barriers and facilita-
tors to women’s use of the investigational product and
their experiences in the VOICE trial. We used data from
the VOICE-C study to explore the type of influences on
clinic attendance in the VOICE trial, and implications
for future HIV prevention trials.Methods
The Johannesburg site for the VOICE trial was located in
Hillbrow, an inner city neighborhood. The trial recruited
participants from within Johannesburg, and as far as
Soweto and Orange Farm townships located about 40
kilometers from the trial site. Participants in the VOICE
trial were expected to complete monthly visits for HIV
testing, safety assessment and product re-supply over a
period of 12 to 36 months, depending on the date of their
enrolment. Clinic visits were scheduled to occur every
28 days following enrolment, with an allowable visit win-
dow of 14 days before and 13 days after this target date.
At the product use end visit (PUEV), participants were
followed for a further eight weeks before finally exiting
the study. The VOICE protocol defined a missed clinic
visit as non-attendance within the visit window. Data on
missed visits was recorded on a missed visit form.
VOICE-C study sample
A random sub-sample of 165 VOICE participants was
preselected for enrolment into VOICE-C. The eligibility
criteria included: enrolment in VOICE; use of the inves-
tigational products for at least three months; not preg-
nant; HIV negative; and not on extended study product
hold. Participants who were selected to participate in
VOICE-C, signed a separate informed consent agree-
ment, and their demographic details were recorded on a
standard case record form (CRF). Further details of this
sample are published elsewhere [15].
Qualitative data collection
Participants were randomly assigned to one of three
interview modalities: a once-off in-depth interview (IDI);
serial ethnographic interviews (EI) repeated up to four
times; or a focus group discussion (FGD). IDI and FGD
took place in a private interview room in the VOICE
study clinic, while EIs took place at the participant’s
residence, or a venue of their choice. The serial nature
of the EIs, combined with their greater focus on the
participant’s everyday life and surroundings, provided
researchers with an opportunity to become better
acquainted with interviewees, learn about changes to
their life experience over time, and in some cases to
observe their living circumstances. Two trained female
interviewers (BM and FM) conducted interviews in a
language preferred by the participant (IsiZulu, SeSotho,
Setswana, Xitsonga, and English). All interviews were
audio-recorded, transcribed, and translated into English,
and reviewed to assess accuracy. VOICE-C participants
received fifty Rand [ZAR 50 = approx. 5 USD] as a reim-
bursement for transport and time.
Participant anonymity was maintained by using partici-
pant identification numbers (PID) on all study material.
Personal information (names and places) mentioned in




18 – 30 80 78
31 – 40 22 22
Education
Secondary incomplete 33 32
Secondary complete 49 48
Attended college/university 20 20
Partnerships
No sexual partner 2 2
Has a sexual partner 100 98
Income
Earns income 58 57
No income 44 43
Child support
Supports children 89 87
Does not support children 13 13
Natal home
In Johannesburg 30 29
Outside Johannesburg 72 71
Totals 102 100
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the transcripts and replaced with pseudonyms.
Data analysis
The study team members coded translated transcripts in
Nvivo (QSR International version 9.0). A socio-ecological
framework that explored those factors that shaped trial
participation and adherence to study products, guided
the analysis. A codebook with 14 key codes was devel-
oped to standardize subsequent coding and an acceptable
level of inter-coder reliability (ICR) was set at more than
80%. At least two team members coded approximately
10% of the transcripts in order to monitor ICR. Our ana-
lysis includes coded transcripts from seven FGD (N = 40),
41 IDI, and 64 serial EI (N = 21 women). Demographic
and visit attendance data were tabulated using SAS
(version 9.3, Cary, NC). Comparison between the VOICE
and VOICE-C samples at the Wits RHI site used baseline
demographic data collected at the VOICE enrolment visit.
Ethical review
The VOICE-C protocol was reviewed and approved by
the Human Research Ethics Committee of the University
of the Witwatersrand (Ref: 090906) and the Institutional
Review Board at RTI International, overseen by the
regulatory infrastructure of the NIH, and monitored by
FHI360 and RTI International.
Our research adheres to the standards contained in the
Qualitative Research Review Guidelines (RATS) (http://
www.biomedcentral.com/authors/rats).
Results
Between July 2010, and August 2012, 144 randomly se-
lected participants were screened for VOICE-C eligibility
during or following their VOICE month three study
visit. Of the 144, 19 were already lost to follow up from
the parent trial and not screened, two declined screen-
ing, and four were not eligible for inclusion. Of the
remaining 106 that consented to participate and were
subsequently enrolled in VOICE-C, 41 completed an
IDI, 40 participated in one of seven exit FGD, 21 com-
pleted two to four serial EIs, and four participants did
not complete any of their planned interviews, resulting
in a total of 102 participants.
We identified the following key themes as barriers or
facilitators to clinic visits: social relations with intimate
partners, household members, extended kin, friends and
co-workers; employment and school attendance; clinic
procedures and clinical care.
Participant characteristics
Overall, 80% of VOICE-C participants (n = 102) were aged
18 to 30 years, 68% had completed secondary school,
and 57% were employed either formally or informally(Table 1). At the time of their first interview, only two
participants were no longer in a sexual relationship, 22%
were married and 87% provided financial support and/or
cared for their own children or that of their relatives. Al-
though all respondents lived in Johannesburg, more than
two thirds (71%) identified their natal home as being out-
side the Johannesburg Metropolitan area, in other prov-
inces, or outside the borders of South Africa. There were
no significant differences in demographic characteristics
between participants included in VOICE-C and those not
included in the VOICE-C cohort (N = 252) [15].
Clinic visit attendance
VOICE participants had a mean of 10.4 follow-up visits
(range: 0–21). 44% of VOICE-C participants missed at
least one visit whereas 62% of non-VOICE-C participants
missed at least one visit (ChiSquare test, p = 0.002). The
mean number of visits missed was lower in the VOICE-C
participants, compared to those not included in VOICE-C
(1.55 vs. 3.79, Wilcoxon Test, p = 0.0003), and more
VOICE-C participants were retained at the PUEV visit
compared to their non-VOICE-C counterparts (97% vs.
87%; ChiSquare test, p = 0.003).
The following were identified through qualitative inter-
views as influencing visit attendance during the VOICE
trial, viz. family, partner and household demands; work
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clinic itself. These are presented in more detail below.
Mothers, daughters, partners – social obligations to others
Participant clinic attendance was influenced by social
expectations from intimate partners, household members
and extended kin. Overall, VOICE-C participants ex-
pressed concerns about disclosing their trial participation
within these relationships, as they were uncertain about
how those close to them would respond to this informa-
tion. For example, a participant disclosed to her husband,
but not to her sister in-law about her participation:
Hey, I think they will say why am I doing this and
think I am a bit immoral, and such things. I don’t
know what they will think. At times I don’t feel
comfortable discussing my private life (age 24, IDI).
Failure to disclose participation in the trial influenced
visit attendance. A participant suggested that one of the
reasons why other participants missed their clinic visits
could be because,
Most of them are not able to use the products and
also [could not] come to the study [clinic] because
they did not tell people in [their] homes that they are
coming to the study [clinic] (age 38, IDI).
Women anticipated that their intimate partners would
react negatively to their participation in the trial. For
example, one woman (age 36, IDI) described her partner
as ‘a bully’ and feared he would prevent her from visiting
the clinic; she decided to conceal her trial participation.
A 20-year-old woman’s partner objected at first because
he felt that the time commitment for clinic visits would
interfere with her responsibilities as a wife and income
earner. However, women who initially experienced re-
sistance from their partners often obtained approval
after they explained the study and convinced their part-
ners of the health benefits provided by the trial, includ-
ing HIV testing. Despite their reservations, some male
partners also supported women’s intentions to partici-
pate in the trial by giving them transport money and
reminding them of clinic appointments. For instance
when the outreach team could not contact a participant
on her phone after she missed her visit they contacted
her partner (she had given consent for the clinic to
contact her partner) and he promised to bring her to the
clinic:
He fetched me from my house…he asked me why
didn’t I go because they [study staff] said I missed my
visit. I said my phone is not working. So he brought
me here [to the trial clinic] (age 19, FGD).Similarly, the attitudes of parents, siblings and other
household members towards trial participation influ-
enced visit attendance. A 23-year-old participant con-
cealed her participation in the trial from her parents,
and when her mother visited her and found out about
her participation she insisted that her daughter withdraw
from the trial. However, she continued with the trial and
attended visits when her mother was not present. On
the other hand, household member support also had a
positive impact on clinic attendance, especially for youn-
ger women still living with their parents. One young
woman recalled that her mother told her: ‘Go and do
what is good for your life…I don’t have a reason to stop
you’ (age 20, IDI). A 26-year-old participant said that
although her mother did not remind her about clinic
visits, she supported her indirectly by looking after her
small child when she visited the clinic.
Family and kinship obligations within a wider social
network were felt strongly by VOICE-C participants. For
many (71%) their natal home was located in another
province or country, far from Johannesburg. Participants
regularly travelled home to visit extended kin on reli-
gious holidays and to participate in rituals like funerals
and weddings that re-establish kinship bonds. A 35-year-
old woman missed four visits to attend her husband’s fu-
neral in Zimbabwe and to observe the mourning period
and cleansing rituals. Another younger participant said
that her father ‘forced her’ to visit home regularly,
resulting in frequent missed VOICE visits (age 21, EI).
However, when participants were able to notify the trial
of prolonged absences from Johannesburg in advance,
women were given extra study products to cover missed
visits.
In search of a better life – work-seekers and students
The majority of participants had financial obligations to
support family members. More than half (57%) of VOICE-
C participants were employed as servers in restaurants
and hotels, cashiers and packers in supermarkets, security
guards, cleaners, administrators, and receptionists. In
many of these situations, the hours were long and pre-
sented difficulties for attending regular monthly clinic
visits. Even those who worked night shifts were too tired
or had other domestic responsibilities to attend to during
the day. One said, ‘The thing is I nearly dropped out be-
cause I could see that it [the trial] was putting me under
pressure’ (age 25, IDI). Being employed did not necessarily
imply stability, as many opportunities were for short-term
contract work. The constant pursuit of employment con-
tributed toward the itinerant nature of many trial partici-
pants, as this woman described:
In this area people move around a lot; today I am
staying here, next month or in two or three months I
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working and I might get a job any time soon
(age 31, IDI).
Moreover, employers were generally unsympathetic to
requests for time off from work, even when presented
with a clinic attendance letter from the trial clinic. A
woman employed as a cleaner elaborated: ‘when I told
her [the employer] that I have to go to the clinic, she
just didn’t understand [agree]. So, I had to dodge [skip
work] sometimes when she is not there’ (age 20, IDI).
Personal circumstances also changed throughout the
duration of the trial. An unmarried participant found a
job as a nurse, and missed five consecutive clinic visits
because of her demanding working hours and infrequent
time off (age 23, FGD). Trial participants who attended
school and university had similar experiences. A college
student described college life as ‘hectic’; she missed two
visits and ran out of tablets (age 20, IDI).
Participants were apprehensive about disclosing their
participation in the trial to employers and workplace
colleagues because of the public secrecy that still per-
vades HIV and AIDS. A participant noted that her work
colleagues would gossip about her and say: ‘uh, uh you
are lying maybe you are sick, why are you taking tablets
every day? Maybe you have HIV/AIDS’ (age 31, IDI).
The clinic context
Participants’ narratives of their experiences within the
clinic setting reflected both negative and positive influ-
ences of the clinic environment on their participation,
and clinic attendance. On the negative side, women
often referred to the lengthy time spent waiting in the
clinic. Study procedures for the monthly visit were
approximately one and half-hours long, while quarterly
visits (‘long visits’) could take up to two and a half hours.
However, waiting time was dependent on the number of
participants at the clinic. Participants expressed their
frustration with waiting time: ‘You wait for the whole
day to wait [to be seen] for 30 minutes, just imagine’
(age 30, EI). ‘Now if I am going for a long visit, I will
start feeling like today I am going to be ill by the end of
the day’ (age 30, EI). Lengthy clinic visits were extremely
disruptive and demotivating, as this woman stated:
Yes, it is the issue of time. Sometimes you would find
that as a person you have other plans, and they get
spoilt because you have to come here to the study
and find [do] their long visits. When you have to
attend your visits then all your plans have to stop,
and that is really irritating, hey. I once missed my
visit and I ended up telling myself that I won’t be
part of the study anymore because I missed my visit
(age 25, EI).Dissatisfaction with the time spent in the clinic could
result in feeling discouraged to return: ‘once you think
Oh my God I will sit on those couches [in the waiting
area] for a long time, that is what makes one to be lazy
to come here again’ (age 19, IDI). A participant observed
another participant who had been waiting for some time:
‘she was waiting and not being attended to. She decided
to leave saying she will never tolerate such a thing, she
just left like that’ (age 21, EI).
Waiting time was particularly inconvenient for work-
ing women. ‘I did not mind waiting at the clinic before,
but now I am working and I must be on time’ (age 21,
EI). Another indicated that her time was worth money:
‘If I lose four hours at work that means I’m losing four
hundred and fifty Rand [ZAR 450 = approx. 45 USD] for
that day’ (age 28, FGD). The long time spent waiting in
the clinic was not only an inconvenience, but was per-
ceived as a lack of consideration for participants’ time.
Yet, unemployed women felt this way too, as they played
multiple roles as child minders and housekeepers, and
were often extremely busy. ‘I dislike coming here [to the
clinic] because we wait too long. In the future do not be
surprised when I do not come here if there is no one at
home’ (age 23, IDI).
For a few participants, the absence of public transport
or living far from the clinic created difficulties to visit
the clinic. Participants who resided far from the clinic
and reached home after dark raised additional concerns
about personal safety. However, participants could notify
the clinic and arrange for a pickup and drop off service
to a central point from which they could catch public
taxis and busses.
While waiting time was a disincentive to attend clinic
visits, the quality of care and positive encounters with
trial staff promoted participation, especially in compari-
son to experiences of low standards of care in public
health facilities and the high cost of private health care
services. The VOICE participants valued the clinical ser-
vices that they received for free such as pap smears and
hepatitis B vaccination. They commented on the friendly
and respectful manner in which the nurses interacted
with them in comparison to government clinics. ‘Even
though the waiting time was long, the VOICE nursing
sisters were very respectful’ (29, FGD). In cases when
participants missed their visits, the efforts to retain them
in the study were regarded very positively. This partici-
pant missed her visits due to work commitments but
returned for her next clinic visit after receiving a phone
call from the clinic.
Hmm, what I like about the VOICE staff members is
that they are more patient than any other studies that
I have ever participated in. Like, at the beginning of
the year I was busy at work and I missed my clinic
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the study. I was so surprised to receive a call from the
VOICE staff member who said ‘you can come
tomorrow and after the clinic visit we will give you a
lift to work. The nurses will also give you the clinic
attendance letter.’ The VOICE staff members
encouraged me to continue with the study because
before they phoned me I thought that I have messed
up everything and I do not qualify to be in the study
anymore. They are very supportive (age 30, EI).
Regular HIV testing also positively motivated women: ‘it
makes me feel that I have to maintain my [HIV negative]
status. I want to take care of myself by making sure that
every month when I visit VOICE I am fine’ (age 21, EI);
‘So, when they test you every month and you discover that
you are still negative you get excited’ (age 25, EI). The
positive and supportive attitudes of the nurses encouraged
women to share their personal problems: ‘friendly nurses
whom I would speak to like they are my friends. Somehow
that made me feel special’ (age 19, IDI).
Reimbursements were also an incentive to visit the
clinic, as this was not only used for transport, but for
personal and household items. ‘I used it to pay my ac-
counts and so on. Yes it was very important because
who is going to buy clothes for my siblings’ (age 24,
IDI). Employed participants also appreciated the reim-
bursement. A single mother of one child who works as a
waitress said: ‘when I am broke in the middle of the
month I am able to buy some foods and other things’
(age 32, IDI).
Discussion
Although overall trial retention in VOICE was satisfac-
tory, participants did not attend monthly clinic visits
consistently, thereby disrupting study product resupply
and counseling, and missing safety assessments. Incon-
sistent clinic visits may therefore have contributed to-
ward the overall poor adherence rates reported for the
VOICE trial [14]. Seeking to understand the reasons for
varying visit attendance, we found that women per-
formed multiple social roles that competed with their
participation in the trial. We also found that the trial
design and expectations may not take into account the
social context in which they are undertaken, and may
need to be adapted to suit the exigencies of participants’
everyday lives.
Discourses about retention in clinical care and research
often use the label ‘defaulter’, implying that participants
intentionally miss study visits. There are a number of
complex reasons why trial participants miss visits [16].
Likewise, our findings suggest that missed visits are fre-
quently unintentional, and due to factors outside indi-
vidual participant’s locus of control. Participants weremembers of kinship networks, wives, girlfriends, care-
givers, income earners, and scholars, and fulfilling these
roles often compromised their ability to attend clinic
visits. Clinic visits interfered with household responsibil-
ities, work and school. As such, trial participants encoun-
tered difficulties when trying to balance their commitment
to these different domains. Employers and educational
authorities were usually inflexible, and constrained trial
participants’ ability to attend clinic visits. On the other
hand, kinship relationships also proved to facilitate par-
ticipation in the trial; male partners and fellow household
members were often supportive of participants and as-
sisted them in attending their clinic visits. In this regard,
disclosure about trial participation was central to whether
support was offered or not. In addition, despite their nega-
tive experiences of waiting for long periods of time in the
clinic, women liked the benefits of the trial, and acted as
responsible participants by re-scheduling visit dates, and
requesting extra supplies of product.
Our findings point to a problematic aspect inherent in
the protocols and procedures that govern the running of
clinical trials. Trial protocols often operate under the as-
sumption that participants are ‘autonomous agents’ and
are relatively free to participate. They seldom address
the dynamics of gender, age, and social relations that
may impact on the running of the trial [17]. These issues
may be managed if incorporated into trial design. For
example: mobile services could ensure consistent access
to product even to those who do not manage to come to
the clinic; visits could be made less frequent and at
times that are suitable for those employed and in school,
reducing the burden on participants; waiting time could
be reduced and time spent in the clinic could be made
more meaningful by providing recreational and learning
opportunities.
Our research highlighted the importance of the quality
of care provided by clinicians, the relationships estab-
lished with the clinic staff as well as the flexibility in ac-
commodating participants’ lives [18]. There is a need for
innovative approaches to promote greater awareness of
the importance of clinical trial participation that could
engender support from household members, male part-
ners, employers, educators, and the community [19].
Clinical trialists can also learn from the relative suc-
cesses in retention in care and treatment settings. For
example, the establishment of patient support clubs has
been effective in retaining patients in antiretroviral
(ARV) treatment settings [20]. Similarly trial participant
groups or clubs may provide participants in prevention
trials with a form of social support and opportunities for
information sharing. This may also foster the creation of
a new identity of being a study participant. Moreover,
capitalizing on the gratitude expressed by participants
for the provision of quality health services, and creating
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increase participants’ sense of being valued and their
commitment to the trial [21].
We recognize that this study has some limitations.
Participants in this sub-sample had higher retention
rates than their non-participating trial counterparts, and
there may be other reasons for missed visits about which
we are not aware. While the VOICE trial was conducted
in 15 sites in Uganda, Zimbabwe, and South Africa,
VOICE-C was undertaken at only one of these sites
located in the inner city of Johannesburg; our findings
may therefore not be generalized to other VOICE sites,
or to other clinical trials. The strength of our findings,
however, lies in the use of multiple qualitative methods
that provided insights into the social context of women’s
daily lives, and the influence that this has on trial
participation.
Conclusions
As we continue the search for HIV prevention options
for women living in sub-Saharan Africa, we need to
recognize that the women who are most at risk of HIV
and who participate in our trials are young, upwardly
mobile and have ambitions beyond that of being passive
participants in a clinical trial. Young women have com-
peting ambitions that make participation in a clinical
trial challenging. By creatively changing the setting or
the culture of the clinical trial itself, researchers may be
able to make it more attractive and engaging.
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